Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer protections ultimately led the board’s special committee to select it as ...

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

D.C. sue to block 23andMe's data sale amid bankruptcy proceedings. Regeneron Pharmaceuticals' $256 million acquisition faces ...

Anne Wojcicki, founder of 23andMe, has successfully repurchased the genetic testing firm out of bankruptcy through her ...

A company like 23andMe can answer a lot of questions for an adoptee. But those answers come with a high cost to privacy.

In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

WilmerHale said it’s representing the law professor tapped to make privacy-related recommendations about the sale of ...

States sue to halt Regeneron's 23andMe acquisition, citing privacy concerns over user DNA data, as a court-ordered report on ...

Anne Wojcicki's nonprofit is set to purchase all significant assets of the bankrupt genetic testing company, 23andMe, for ...